Share on StockTwits

PharMerica (NYSE:PMC) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a research note issued to investors on Friday. The firm currently has a $31.40 target price on the stock. Zacks‘s target price points to a potential upside of 18.27% from the company’s current price.

A number of other firms have also recently commented on PMC. Analysts at Barclays initiated coverage on shares of PharMerica in a research note on Thursday, July 17th. They set an “underweight” rating on the stock. Separately, analysts at ISI Group reiterated a “positive” rating on shares of PharMerica in a research note on Wednesday, July 2nd. Finally, analysts at KeyCorp reiterated a “buy” rating on shares of PharMerica in a research note on Monday, June 9th. They now have a $33.00 price target on the stock, up previously from $31.00. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the stock. PharMerica has an average rating of “Buy” and an average target price of $27.08.

Shares of PharMerica (NYSE:PMC) traded up 1.10% on Friday, hitting $26.55. 170,027 shares of the company’s stock traded hands. PharMerica has a one year low of $11.84 and a one year high of $30.48. The stock has a 50-day moving average of $27.78 and a 200-day moving average of $26.77. The company’s market cap is $798.1 million.

PharMerica (NYSE:PMC) last released its earnings data on Tuesday, August 5th. The company reported $0.40 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.36 by $0.04. The company had revenue of $448.60 million for the quarter, compared to the consensus estimate of $432.70 million. During the same quarter in the prior year, the company posted $0.44 earnings per share. The company’s quarterly revenue was up 4.1% on a year-over-year basis. On average, analysts predict that PharMerica will post $1.51 earnings per share for the current fiscal year.

PharMerica Corporation is an institutional pharmacy services company, which services healthcare facilities and provides management pharmacy services to hospitals.

To view Zacks’ full report, visit Zacks’ official website.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.